52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Onkure And Pfizer Enter Agreement To Evaluate Combination Of Oki-179 And Binimetinib
EMD Sereno Says Bavencio Pivotal Phase III Javelin Bladder 100 Results Published In The New England Journal Of Medicine
Pfizer Sees $18 - $20 Bln Lost Revenue Due To Exclusivity Losses Beginning In 2026 - Investor Day
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.
Biotechnology & Drugs
235 E 42ND ST
NEW YORK, NY
Chairman of the Board, Chief Executive Officer
John D. Young
Chief Business Officer, Group President
Frank A. D'Amelio
Chief Financial Officer, Executive Vice President - Business Operations and Global Supply
Group President, Pfizer Biopharmaceuticals Group
Chief Human Resource Officer, Executive Vice President
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
The U.S. Food and Drug Administration is expected to soon announce new, more stringent standards for an emergency authorization of a COVID-19 vaccine, lowering the chances that one might be cleared for use before the Nov. 3 election, the Washington Post reported on Tuesday.
(Updates Moderna, adds Beijing Wantai Biological Pharmacy, COVAXX, University Hospital Tuebingen, China's Institute of Biotechnology) Sept 21 (Reuters) - More than 150 potential vaccines are being developed and tested globally to stop the COVID-19 pandemic, with 38 in human...
U.S. President Donald Trump on Monday suggested Pfizer Inc could secure the first U.S. approval of a COVID-19 vaccine in coming weeks, saying a contender by Johnson & Johnson could come later.
Bristol Myers Squibb Co's cancer immunotherapy Opdivo in combination with Exelixis Inc's Cabometyx reduced the risk of death by 40% in previously untreated patients with advanced kidney cancer, according to data from a late-stage study to be presented on Saturday.
Pfizer Inc is betting that its coronavirus vaccine candidate will show clear evidence of effectiveness early in its clinical trial, according to the company and internal documents reviewed by Reuters that describe how the trial is being run.
BioNTech is buying a production site for the COVID-19 vaccine it is developing with Pfizer, aiming to boost output by several hundred million doses next year, and hopes to have the shot ready to file for approval in October.
BioNTech <BNTX.O> expects that the experimental COVID-19 vaccine it is developing with Pfizer <PFE.N> can be stored at refrigerator temperatures for at least two weeks, seeking to allay concerns that the compound may have to be deep-frozen.
U.S. President Donald Trump on Tuesday said a vaccine against the deadly coronavirus could be three or four weeks away, despite cautionary notes sounded by some U.S. public health officials about that accelerated timeline.
Pfizer Inc said on Tuesday participants were showing mild-to-moderate side effects when given either the company's experimental coronavirus vaccine or a placebo in an ongoing late-stage study.
U.S. President Donald Trump on Tuesday said a vaccine against the deadly coronavirus could be three or four weeks away, underscoring predictions made by U.S. public health officials and Pfizer Inc earlier this month.
Pfizer Inc said on Tuesday patients were showing mild-to-moderate tolerability to either the company's experimental coronavirus vaccine or a placebo in an ongoing late-stage study.
Germany awarded $745 million in funding to biotech firms BioNTech and CureVac on Tuesday to speed up work on COVID-19 vaccines and expand German production capacity.
* UK parliament to vote on plan to break Brexit divorce treaty
* PFIZER CEO SAYS STILL SEES AT LEAST 6% CAGR GROWTH OVER THE NEXT 5 YRS - INVESTOR DAY
Pfizer Inc <PFE.N> said on Monday that it had enrolled more than 29,000 people in its 44,000-volunteer trial to test the experimental COVID-19 vaccine it is developing with German partner BioNTech. <22UAy.F>
Pfizer Inc and BioNTech SE on Saturday proposed to the U.S Food and Drug Administration (FDA) to expand their Phase 3 pivotal COVID-19 vaccine trial to about 44,000 participants while increasing the diversity of the trial population.
Pfizer Inc and BioNTech SE have proposed to the U.S Food and Drug Administration (FDA) to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to about 44,000 participants, the companies said on Saturday.
* PFIZER AND BIONTECH PROPOSE EXPANSION OF PIVOTAL COVID-19 VACCINE TRIAL
(This Sept 9 story corrects Pfizer executive's title in 17th paragraph)
The European Commission said on Wednesday it had entered final stage talks with BioNTech-Pfizer to purchase up to 300 million doses of a potential vaccine against COVID-19.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.